Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Hitachi Soon To Market Precise Protein Spectrometer

This article was originally published in PharmAsia News

Executive Summary

Hitachi High-Technologies of Japan plans to begin marketing soon a highly precise mass spectrometer for analyzing proteins. The trick in analyzing protein is to do so without destroying various molecules that may be attached to the protein. Such molecules are what identify the state of the disease involved and precision in developing more-precise drugs to deal with the disease. Hitachi says its spectrometer is five times as precise as current models and can analyze several thousand proteins in no more than 2.5 hours versus the current 10 hours for current analyzers. (Click here for more - a subscription may be required

You may also be interested in...



A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

Innovation-Friendly? Cases Indicate How Far China's Willing To Protect Patents

Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.

Byondis: Taking Precision Medicine To The Next Level

Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel